BRPI0702640A - processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos - Google Patents
processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicosInfo
- Publication number
- BRPI0702640A BRPI0702640A BRPI0702640-4A BRPI0702640A BRPI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A BR PI0702640 A BRPI0702640 A BR PI0702640A
- Authority
- BR
- Brazil
- Prior art keywords
- application
- receptor sites
- flavonoid
- benzodiazepine receptor
- brain
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21H—OBTAINING ENERGY FROM RADIOACTIVE SOURCES; APPLICATIONS OF RADIATION FROM RADIOACTIVE SOURCES, NOT OTHERWISE PROVIDED FOR; UTILISING COSMIC RADIATION
- G21H5/00—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for
- G21H5/02—Applications of radiation from radioactive sources or arrangements therefor, not otherwise provided for as tracers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Abstract
PROCESSO DE RADIOMARCAçãO DE FLAVONóIDES E SUA APLICAçãO EM DIAGNóSTICO IN VIVO DE DISFUNçõES CEREBRAIS RELACIONADAS AOS SìTIOS RECEPTORES BENZODIAZEPìNICOS. Compreende um estudo referente ao desenvolvimento radioquímico de flavonóides radiomarcados e aplicação in vivo como agentes de imageamento cerebral frente a sítios receptores benzodiazepínicos, utilizando-se técnicas tomográficas, em dito processo foi estudada a marcação de flavonóides via substituição eletrofilica aromática e biodistribuição de flavona radiomarcada em camungongos Swiss. Os resultados indicam elevada concentração do radiotraçador no cérebro, principalmente até 30 minutos após a injeção do radiocomposto, compatíveis com a utilização clínica como agente de imageamento e com grande potencial para aplicação em medicina nuclear diagnóstica.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0702640-4A BRPI0702640A (pt) | 2007-01-10 | 2007-01-10 | processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos |
PCT/BR2008/000005 WO2008083454A1 (en) | 2007-01-10 | 2008-01-08 | Process for flavonoids radiolabeling and its application on in vivo diagnosis of brain malfunctions related to benzodiazepine receiving sites |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0702640-4A BRPI0702640A (pt) | 2007-01-10 | 2007-01-10 | processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0702640A true BRPI0702640A (pt) | 2008-08-26 |
Family
ID=39608273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0702640-4A BRPI0702640A (pt) | 2007-01-10 | 2007-01-10 | processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos |
Country Status (2)
Country | Link |
---|---|
BR (1) | BRPI0702640A (pt) |
WO (1) | WO2008083454A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009102498A1 (en) * | 2008-02-14 | 2009-08-20 | Siemens Medical Solutions Usa, Inc. | Novel imaging agents for detecting neurological dysfunction |
US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
EP2323697A2 (en) | 2008-07-24 | 2011-05-25 | Siemens Medical Solutions USA, Inc. | Imaging agents useful for identifying ad pathology |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
EP2411057B1 (en) | 2009-03-23 | 2020-05-06 | Eli Lilly and Company | Imaging agents for detecting neurological disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450149A (en) * | 1981-06-15 | 1984-05-22 | Research Corporation | Radiohalogenation method |
-
2007
- 2007-01-10 BR BRPI0702640-4A patent/BRPI0702640A/pt not_active Application Discontinuation
-
2008
- 2008-01-08 WO PCT/BR2008/000005 patent/WO2008083454A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008083454A1 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kuntner et al. | Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11 C] verapamil PET | |
Kuntner et al. | Quantitative preclinical PET imaging: opportunities and challenges | |
Zimmer et al. | PET radiotracers for molecular imaging in the brain: past, present and future | |
Bankstahl et al. | Tariquidar-induced P-glycoprotein inhibition at the rat blood–brain barrier studied with (R)-11C-verapamil and PET | |
Yamamoto et al. | Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys | |
Collingridge et al. | In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope | |
Ory et al. | PET radioligands for in vivo visualization of neuroinflammation | |
Zheng et al. | [11C] Choline as a PET biomarker for assessment of prostate cancer tumor models | |
Herfert et al. | Quantitative rodent brain receptor imaging | |
BRPI0702640A (pt) | processo de radiomarcação de flavonóides e sua aplicação em diagnóstico in vivo de disfunções cerebrais relacionadas aos sìtios receptores benzodiazepìnicos | |
Pinborg et al. | No change in [11C] CUMI‐101 binding to 5‐HT1A receptors after intravenous citalopram in human | |
Parent et al. | PET imaging of cholinergic deficits in rats using [18F] fluoroethoxybenzovesamicol ([18F] FEOBV) | |
Elmenhorst et al. | Test‐retest stability of cerebral mGluR5 quantification using [11C] ABP688 and positron emission tomography in rats | |
Shen et al. | Radiosynthesis and first-in-human PET/MRI evaluation with clinical-grade [18 F] FTC-146 | |
McCormick et al. | Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release | |
Patel et al. | Bimodal imaging of inflammation with SPECT/CT and MRI using iodine-125 labeled VCAM-1 targeting microparticle conjugates | |
Takano et al. | SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study | |
Fan et al. | 68Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human Glioblastoma | |
WO2009143101A3 (en) | Gastrin releasing peptide compounds | |
Montemagno et al. | In vivo biodistribution and efficacy evaluation of NeoB, a radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor | |
Kim et al. | PET measurement of “GABA shift” in the rat brain: A preclinical application of bolus plus constant infusion paradigm of [18F] flumazenil | |
Hwang et al. | Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18 F] AMG 580 in non-human primates | |
Ziebell | Evaluation of the superselective radioligand [123I] PE2I for imaging of the dopamine transporter in SPECT | |
Soares et al. | Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F] deuteroaltanserin | |
Tsartsalis et al. | 5-HT2A receptor SPECT imaging with [123I] R91150 under P-gp inhibition with tariquidar: More is better? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of an application: publication of a patent application or of a certificate of addition of invention | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) | ||
B08E | Application fees: requirement for complementation of annuity fee |
Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 3A., 4A., 7A. ANUIDADE(S), DE ACORDO COM TABELA VIGENTE, REFERENTE A(S) GUIA(S) DE RECOLHIMENTO 0000220903513720, 0000221002127402 E 0000221303691510, RESPECTIVAMENTE E COMPROVAR O RECOLHIMENTO DA 9A. ANUIDADE E A TAXA DE RESTAURACAO DA 5A. |
|
B08G | Application fees: restoration | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |